Efficacy and Safety Analysis of Shensong Yangxin Capsules Combined with Metoprolol Succinate Sustained-release Tablets in the Treatment of Premature Ventricular Beats
Objective:To explore the efficacy and safety of Shensong Yangxin Capsules combined with Metoprolol Succinate Sustained-release Tablets in the treatment of premature ventricular beats(PVB).Method:A total of 74 patients with PVB treated in the Pingxiang NO.2 People's Hospital from October 2021 to October 2023 were divided into two groups by random number table method,with 37 cases in each group.The control group was treated with Metoprolol Succinate Sustained-release Tablets,and the observation group was treated with Shensong Yangxin Capsules on the basis of the control group.The clinical effects,symptom scores,inflammatory factors,cardiac function indexes and incidence of adverse reactions were compared between the two groups.Result:Compared with the control group,the total effective rate of the observation group was higher,the difference was statistically significant(P<0.05).After treatment,the symptom scores,C reactive protein(CRP),interleukin-6(IL-6),matrix metalloproteinase-9(MMP-9),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)in the observation group were lower than those in the control group,the left ventricular ejection fraction(LVEF)was higher than that of the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the two groups was 13.51%and 8.11%,respectively,the difference was not statistically significant(P>0.05).Conclusion:The combination of Shensong Yangxin Capsules and Metoprolol Succinate Sustained-release Tablets in the treatment of PVB has good clinical effect,can accelerate the remission of clinical symptoms,improve cardiac function,reduce inflammation reactions,and is safe and reliable.
国家科技期刊平台
NSTL
万方数据
